On this episode of WellBuilt, Jon sits down with Cory Henderson PhD, Co-founder and CEO of Evolve, to unpack the science, hype, and real opportunity behind GLP-1 supplements—and why the next chapter of preventative health may look very different than pharmaceuticals.
Evolve isn't trying to compete with injectable GLP-1 drugs. Instead, the company is building a new category they calls biomimetics: oral, consumer-accessible products designed to mimic the body's own biology, without harsh side effects or long-lasting interventions.
They cover:
🧬 How Cory's background in genetic engineering and public health led him to rethink GLP-1 for healthy, performance-minded consumers.
💊 Why pharmaceutical GLP-1s behave so differently than natural hormone signaling and how half-life, receptor balance, and delivery method matter.
⚖️ The gap between supplements that don't work and drugs that weren't designed for healthy people.
📉 Early customer feedback around appetite control, energy, metabolic health, and sustainable weight loss.
🧠 Why behavior change, education, and expectation-setting matter more than "magic pills."
🔬 What biomimetics means, how it differs from traditional supplements, and where this category could expand next (longevity, muscle growth, women's health, and more).
🧪 How Evolve designs orally available biologics using natural proteins and why oral delivery changes safety, personalization, and adoption.
📚 How Cory thinks about trust, misinformation, and consumer education in an under-regulated supplement market.
🚀 Why preventative health, not disease treatment, is the real long-term opportunity, and how consumer health products may evolve over the next decade.
🚴 Cory also shares his own experience using Evolve for performance and metabolic health and how personalization plays a role in dosing.
Enjoy!